While the pace of startup formation in biotech has been accelerating over the past decade, early signs suggest the malaise in the markets is finding its way back into the venture creation ecosystem.
April 4, 2022 |   LifeSciVC
Biotech’s January Chill: Big Drop In New Startups
March 29, 2022 |   From the Trenches
Collaborating with Patient Advocacy Groups to Advance Rare Disease Awareness and Support
Over my many years in the biopharma industry, working across disease areas, including orphan indications, I have learned that to impact patients’ lives credibly and meaningfully, we must raise awareness about the conditions we are attempting to treat. One of the most effective ways is to engage with patient advocacy groups who are more closely connected to patients and caregivers and have a deep knowledge of their needs. Access to patient groups is particularly important for work related to rare disease indications given the challenging combination of urgent patient needs, and limited resources and knowledge.
By Ivana Magovčević-Liebisch, CEO of Vigil Neuroscience, as part of the From The Trenches feature of LifeSciVC.
March 28, 2022 |   LifeSciVC
In Defense Of Early Stage Biotech IPOs
There’s “just too many early stage companies going public”, or so goes one of the most common lamentations about the current state of the biotech market.
March 21, 2022 |   LifeSciVC
Innovation Ecosystem: A Year Of Risk-Off Correlations
Misery loves company, and so it goes with the stock market for the innovation ecosystem these days.
March 17, 2022 |   LifeSciVC
Biotech Bears: Jumping A Lower Bar Or A Higher One?
Biotech sentiment is super bearish today, as the sector has been crushed over the last year. There’s blood in the water, especially for small and mid-cap players, and everyone’s looking for what caused the carnage.